These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34923809)

  • 41. The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies.
    Haji Ali Afzali H; Street J; Merlin T; Karnon J
    Int J Technol Assess Health Care; 2021 Jan; 37():e22. PubMed ID: 33455592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. STAKEHOLDER INVOLVEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN LATIN AMERICA.
    Pichon-Riviere A; Soto N; Augustovski F; Sampietro-Colom L
    Int J Technol Assess Health Care; 2018 Jan; 34(3):248-253. PubMed ID: 29888698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systems Science and Evidence-Informed Deliberation to Mitigate Dilemmas in Situations of Dual Agency at the Hospital Level Comment on "Dual Agency in Hospitals: What Strategies Do Managers and Physicians Apply to Reconcile Dilemmas Between Clinical and Economic Considerations".
    Bijlmakers L
    Int J Health Policy Manag; 2022 Oct; 11(10):2337-2339. PubMed ID: 35247940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Knowledge mobilization in the context of health technology assessment: an exploratory case study.
    Fournier MF
    Health Res Policy Syst; 2012 Apr; 10():10. PubMed ID: 22472141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Steps toward improving ethical evaluation in health technology assessment: a proposed framework.
    Assasi N; Tarride JE; O'Reilly D; Schwartz L
    BMC Med Ethics; 2016 Jun; 17(1):34. PubMed ID: 27267369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA.
    Kristensen FB; Husereau D; Huić M; Drummond M; Berger ML; Bond K; Augustovski F; Booth A; Bridges JFP; Grimshaw J; IJzerman MJ; Jonsson E; Ollendorf DA; Rüther A; Siebert U; Sharma J; Wailoo A
    Value Health; 2019 Jan; 22(1):13-20. PubMed ID: 30661627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?
    ; Neumann PJ; Drummond MF; Jönsson B; Luce BR; Schwartz JS; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2010 Jan; 26(1):71-8. PubMed ID: 20059783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries.
    Fontrier AM; Visintin E; Kanavos P
    Pharmacoecon Open; 2022 May; 6(3):315-328. PubMed ID: 34845671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions.
    Nicod E; Kanavos P
    Health Policy; 2012 Dec; 108(2-3):167-77. PubMed ID: 23088802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes.
    Frønsdal KB; Facey K; Klemp M; Norderhaug IN; Mørland B; Røttingen JA
    Int J Technol Assess Health Care; 2010 Jul; 26(3):309-16. PubMed ID: 20584360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addressing uncertainty in relative effectiveness assessments by HTA organizations.
    Vreman RA; Strigkos G; Leufkens HGM; Schünemann HJ; Mantel-Teeuwisse AK; Goettsch WG
    Int J Technol Assess Health Care; 2022 Jan; 38(1):e17. PubMed ID: 35094740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health technology assessment in Brazil - an international perspective.
    Lima SGG; Brito C; Andrade CJC
    Cien Saude Colet; 2019 May; 24(5):1709-1722. PubMed ID: 31166506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.